Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

STI571: targeting BCR-ABL as therapy for CML.

M J Mauro1, B J Druker

  • 1Leukemia Program, Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 Sam Jackson Park Road, Portland, OR 97201, USA. maurom@ohsu.edu

The Oncologist
|June 26, 2001
PubMed
Summary

STI571, a targeted therapy, shows high effectiveness in chronic myelogenous leukemia (CML) patients. This signal transduction inhibitor demonstrates significant hematologic and cytogenetic responses with minimal toxicity in clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Knight Scholars Program: A Tiered Three-Year Mentored Training Program for Urban and Rural High School High School Students Increases Interest and Self-Efficacy in Interprofessional Cancer Research.

Journal of STEM outreach·2023
Same author

Recurrent cyclin D2 mutations in myeloid neoplasms.

Leukemia·2017
Same author

Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia.

Leukemia·2016
Same author

Age-related mutations and chronic myelomonocytic leukemia.

Leukemia·2015
Same author

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.

Leukemia·2015
Same author

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.

Leukemia·2015

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Chronic myelogenous leukemia (CML) is driven by the bcr-abl tyrosine kinase.
  • Targeted therapies offer a promising approach for treating human cancers by addressing specific molecular abnormalities.
  • STI571 is a rationally designed inhibitor of abl tyrosine kinases, including bcr-abl.

Purpose of the Study:

  • To evaluate the safety and efficacy of therapeutic agent STI571 in patients with chronic myelogenous leukemia (CML).
  • To determine the maximally effective dose and response rates of STI571 in different phases of CML.

Main Methods:

  • Phase I study: 83 CML patients treated with oral STI571 (25-1,000 mg daily) after failure of interferon therapy.
  • Phase II study: 233 CML patients treated with 400 or 600 mg of STI571 in the accelerated phase.

Related Experiment Videos

  • Ongoing Phase III trial comparing STI571 with interferon and cytosine arabinoside in newly diagnosed CML patients.

    • Main Results:

    • Phase I: No dose-limiting toxicity observed; 300 mg identified as maximally effective dose.
    • Phase I: At ≥300 mg, 98% complete hematologic response, 13% complete cytogenetic response, 31% major cytogenetic response.
    • Phase II: 91% hematologic response, 63% complete hematologic response in accelerated phase CML.

    Conclusions:

    • STI571 is a well-tolerated and effective treatment for CML, demonstrating significant hematologic and cytogenetic responses.
    • Targeting the bcr-abl tyrosine kinase with STI571 is a crucial strategy in CML treatment.
    • Long-term follow-up data from ongoing trials are necessary for integrating STI571 into CML treatment algorithms.